Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients

Background and Aims: Lactose intolerance (LI) is a global problem affecting more than half of the world’s population. An ultra-purified, high-concentration galacto-oligosaccharide, RP-G28, is being developed as a treatment for patients with LI. The efficacy and safety of RP-G28 in reducing symptoms...

Descripción completa

Detalles Bibliográficos
Autores principales: Chey, William, Sandborn, William, Ritter, Andrew J., Foyt, Howard, Azcarate-Peril, M. Andrea, Savaiano, Dennis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231374/
https://www.ncbi.nlm.nih.gov/pubmed/32290344
http://dx.doi.org/10.3390/nu12041058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231374/
https://www.ncbi.nlm.nih.gov/pubmed/32290344
http://dx.doi.org/10.3390/nu12041058

Ejemplares similares